Table 2.
Study characteristics and summary data extracted from the studies included in the analysis
| SBP |
DBP |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug | Final dose | Titration type | n | Mean age (years) | Prop. male | Baseline | Change | SD of change | Baseline | Change | SD of change | References |
| Candesartan | 2 | None | 59 | 54 | 0.49 | 152 | −8.9 | 14.7 | 99 | −7.1 | 8.82 | Reif et al. (18)* |
| 4 | None | 63 | 55 | 0.7 | 152 | −10.5 | 13.97 | 100 | −8.4 | 8.3 | Reif et al. (18)* | |
| 8 | None | 82 | 60 | 0.57 | 169 | −14 | NA | 102 | −9 | NA | Andersson and Neldam (19) | |
| 60 | 55 | 0.57 | 154 | −9.9 | 14.03 | 101 | −8.7 | 8.5 | Reif et al. (18) | |||
| 16 | None | 84 | 59 | 0.67 | 168 | −16 | NA | 103 | −10 | NA | Andersson and Neldam (19) | |
| 60 | 55 | 0.63 | 153 | −10.7 | 14.82 | 100 | −7.8 | 8.89 | Reif et al. (18) | |||
| Forced | 91 | 54 | 0.62 | 150.1 | −11.1 | NA | 100.2 | −9.4 | NA | Zuschke et al. (20) | ||
| 94 | 53 | 0.61 | 151.9 | −12.6 | NA | 99.8 | −10.3 | NA | Zuschke et al. (20) | |||
| 32 | None | 59 | 55 | 0.7 | 152 | −12.6 | 14.5 | 100 | −10.2 | 8.43 | Reif et al. (18) | |
| Forced | 332 | 54.2 | 0.578 | 152.6 | −13.3 | NA | 100.1 | −10.9 | NA | Bakris et al. (21) | ||
| 123 | 53 | 0.53 | 144.9 | −15.2 | 11.88 | 94.2 | −10.2 | 7.64 | Kloner et al. (22) | |||
| 307 | 55.5 | 0.583 | 153.6 | −13.4 | NA | 100.4 | −10.5 | NA | Vidt et al. (23) | |||
| Irbesartan | 37.5 | None | 40 | 55 | 0.65 | 151 | −7.5 | 10.5 | 100 | −7.1 | 6.7 | Kochar et al. (24)* |
| 75 | None | 55 | 56.7 | 0.67 | 157 | −6.6 | 11.79 | 101.4 | −6.1 | 7.56 | Fogari et al. (25)* | |
| 100 | None | 36 | 55 | 0.65 | 151 | −11.1 | 12.5 | 100 | −9.1 | 8.9 | Kochar et al. (24)* | |
| 79 | 52.8 | 0.69 | 149.8 | −10.5 | 11.73 | 100.7 | −9.7 | 7.55 | Pool et al. study 2 (11)* | |||
| 150 | None | 53 | 54.6 | 0.6 | 158.9 | −11.4 | 12.38 | 101 | −8.3 | 7.86 | Fogari et al. (25) | |
| 57 | 54.1 | 0.63 | 156 | −11.6 | 11.63 | 101.3 | −9.7 | 7.4 | Fogari et al. (25) | |||
| 134 | 56.1 | 0.493 | 152.8 | −12.5 | 14.01 | 99.4 | −8.88 | 8.57 | Gradman et al. (26) | |||
| 142 | 53.1 | 0.54 | 155.3 | −12.1 | 13.7 | 101.1 | −9.7 | 7.75 | Kassler-Taub et al. (27) | |||
| 145 | 51.9 | 0.586 | 156 | −11 | NA | 104 | −9.9 | NA | Oparil et al. (28) | |||
| 200 | None | 75 | 52.8 | 0.69 | 149.8 | −10.1 | 11.52 | 100.7 | −9.8 | 7.36 | Pool et al. study 2 (11)* | |
| 300 | None | 140 | 55.6 | 0.57 | 155.4 | −16.4 | 13.37 | 100.4 | −11.7 | 7.57 | Kassler-Taub et al. (27) | |
| 43 | 55 | 0.65 | 151 | −14.9 | 9.5 | 100 | −10.2 | 5.8 | Kochar et al. (24) | |||
| 78 | 52.8 | 0.69 | 149.8 | −13 | 11.75 | 100.7 | −11.6 | 7.51 | Pool et al. study 2 (11) | |||
| Losartan | 50 | None | 83 | 51.8 | 0.56 | 164 | −14.4 | NA | 113.6 | −10.6 | NA | Ali et al. (29) |
| 83 | 59 | 0.57 | 168 | −15 | NA | 104 | −9 | NA | Andersson and Neldam (19) | |||
| 127 | 53.2 | 0.65 | NA | NA | NA | 102.2 | −7.9 | 9 | Ikeda et al. (30) | |||
| 57 | 56 | 0.58 | 162.4 | −10.3 | 13.59 | 100.7 | −6 | 7.55 | Mallion et al. (31) | |||
| 93 | 54.6 | 0.42 | NA | NA | NA | 100.8 | −9.1 | 7.6 | Monterroso et al. (32) | |||
| 146 | 51.6 | 0.623 | 157 | −9.5 | NA | 104 | −8.2 | NA | Oparil et al. (28) | |||
| 100 | None | 138 | 55 | 0.5 | 153.3 | −11.3 | 13.39 | 100.6 | −8.7 | 7.52 | Kassler-Taub et al. (27) | |
| Forced | 322 | 54.1 | 0.584 | 152 | −9.8 | NA | 99.9 | −8.7 | NA | Bakris et al. (21) | ||
| 121 | 57 | 0.47 | 162.5 | −16 | 16.4 | 100.67 | −10 | 9.4 | Chung et al. (33) | |||
| 200 | 51.3 | 0.6 | 155 | −13.4 | 12.63 | 103.6 | −11.5 | 8.3 | Giles et al. (12)† | |||
| 545 | 55.7 | 0.575 | 157.4 | −12.8 | NA | 101.6 | −9.7 | NA | Hedner et al. (34) | |||
| 304 | 55.1 | 0.589 | 152.2 | −10.1 | NA | 100.2 | −9.1 | NA | Vidt et al. (23) | |||
| 103 | 55 | 0.62 | 148 | −7.3 | 18.27 | 95 | −6.7 | 11.16 | White et al. (35) | |||
| Elective | 123 | 55.1 | 0.63 | NA | NA | NA | 102.2 | −8.6 | 8.3 | Ikeda et al. (30)* | ||
| Olmesartan | 20 | None | 145 | 52.4 | 0.669 | 157 | −11.3 | NA | 104 | −11.5 | NA | Oparil et al. (28) |
| 40 | Forced | 199 | 52.2 | 0.63 | 155.4 | −13.9 | 12.6 | 103.5 | −11.7 | 8.28 | Giles et al. (12) | |
| Telmisartan | 40 | None | 71 | 49.2 | 0.52 | 151.1 | −17.6 | NA | 97.2 | −11.7 | NA | Chen et al. (36) |
| 57 | 58 | 0.67 | 161.9 | −14.2 | 13.59 | 100.8 | −8.6 | 7.55 | Mallion et al. (31) | |||
| 75 | 51 | 0.56 | 153.2 | −12.2 | 14.72 | 100.7 | −10.7 | 8.66 | McGill (37) | |||
| 72 | 54.6 | 0.69 | 155.2 | −11.6 | 13.58 | 100.8 | −9.3 | 7.64 | Smith et al. (38) | |||
| 80 | None | 54 | 57 | 0.65 | 164.2 | −15.9 | 13.23 | 101.8 | −9.7 | 8.08 | Mallion et al. (31) | |
| 77 | 51 | 0.56 | 153.2 | −15.4 | 14.92 | 100.7 | −11.5 | 8.77 | McGill (37) | |||
| 30 | 51.1 | 0.6 | 167.4 | −27.7 | NA | 102.2 | −12.4 | NA | Nalbantgil et al. (39) | |||
| 72 | 54.4 | 0.57 | 153.7 | −11.8 | 13.58 | 100 | −9.7 | 7.64 | Smith et al. (38)* | |||
| 120 | None | 73 | 53.2 | 0.66 | 151.9 | −10 | 12.82 | 100.2 | −8.8 | 7.69 | Smith et al. (38)* | |
| 160 | None | 75 | 53.4 | 0.68 | 154.2 | −11.9 | 12.99 | 100.5 | −8.6 | 7.79 | Smith et al. (38)* | |
| Valsartan | 40 | None | 127 | 55 | 0.57 | 153.7 | −11.8 | 11.95 | 99.2 | −10.1 | 7.55 | Philipp et al. study 1 (40)* |
| 80 | None | 94 | 54.1 | 0.49 | NA | NA | NA | 100.8 | −7 | 8.5 | Monterroso et al. (32) | |
| 142 | 51.7 | 0.577 | 155 | −8.4 | NA | 104 | −7.9 | NA | Oparil et al. (28) | |||
| 124 | 53.1 | 0.45 | 153.2 | −12.9 | 11.8 | 99.2 | −9.7 | 7.46 | Philipp et al. study 1 (40) | |||
| 58 | 56 | 0.66 | 152.4 | −11.2 | 12.57 | 99 | −10.5 | 8.15 | Pool et al. (41) | |||
| 160 | None | 666 | 55.3 | 0.52 | 160.2 | −15.7 | 13.32 | 101.3 | −10.8 | 8.43 | Mallion et al. (42) | |
| 1884 | 55.2 | 0.553 | 158.6 | −12.97 | 16 | 99.81 | −10.69 | 9.59 | Parati (43) | |||
| 128 | 53 | 0.54 | 152 | −15.1 | 11.99 | 98.9 | −11 | 7.58 | Philipp et al. study 1 (40) | |||
| 207 | 56.8 | 0.44 | 155.6 | −20.2 | 13.96 | 98.9 | −13.3 | 9.06 | Philipp et al. study 2 (40) | |||
| 166 | 52.2 | 0.52 | 149.6 | −14.5 | 12.63 | 98.9 | −11.7 | 8.37 | Pool et al. (41) | |||
| 59 | 55.1 | 0.49 | 154.7 | −15.5 | 12.67 | 99.1 | −11 | 8.22 | Pool et al. (41) | |||
| Forced | 551 | 54.9 | 0.567 | 157 | −13.8 | NA | 101.4 | −10.5 | NA | Hedner et al. (34) | ||
| 320 | None | 128 | 56.8 | 0.52 | 154.6 | −15.7 | 11.99 | 99.3 | −13.4 | 7.58 | Philipp et al. study 1 (40) | |
| 208 | 56.7 | 0.52 | 157.5 | −19.8 | 13.99 | 99.1 | −13.3 | 9.09 | Philipp et al. study 2 (40) | |||
| 170 | 52.5 | 0.55 | 149.5 | −13.7 | 12.78 | 99 | −11.3 | 8.47 | Pool et al. (41) | |||
| 60 | 56.8 | 0.52 | 153.4 | −16.5 | 12.55 | 98.9 | −11.3 | 8.13 | Pool et al. (41) | |||
| Forced | 197 | 52.2 | 0.66 | 154.3 | −14.8 | 12.17 | 103.3 | −12.4 | 7.88 | Giles et al. (12) | ||
| 455 | 52.4 | 0.62 | 154.2 | −12.8 | 13.86 | 100.3 | −9.7 | 8.75 | Oparil et al. (44) | |||
| 1873 | 54.6 | 0.565 | 159.19 | −16.1 | 15.6 | 99.88 | −11.97 | 9.51 | Parati (43) | |||
*
Data from all study arms are used in the model for imputing missing SDs, even if the study arm contains a dose for which the treatment effect is not estimated. Such arms are indicated here.
†
Losartan 100 mg is given in 50 mg bid. Data on file was also used from Parati (43). SBP, systolic blood pressure; DBP, diastolic blood pressure; Prop., proportion.